Longitude Rx Taps Veteran Exec to Scale Health System Pharmacy Model

IRVING, Texas – March 31, 2026 – Longitude Rx, the specialty pharmacy services organization owned by a consortium of major health systems, has appointed Stacy Walton as its inaugural Chief Commercial Officer, a strategic move signaling its intent to aggressively expand its disruptive model in the high-stakes specialty drug market.

Walton, a seasoned executive with over three decades of experience spanning clinical care and commercial strategy, will take the helm of all commercial functions. Her appointment comes as Longitude Rx, established in 2024, moves to scale its platform beyond its five founding health systems. The organization aims to offer a compelling alternative to traditional pharmacy benefit manager (PBM)-dominated channels, which have long frustrated providers with access barriers and fragmented care.

In her new role, Walton is tasked with unifying market access, payer strategy, and growth into a cohesive commercial engine. Her key priorities will be to expand health system access to limited distribution drugs (LDDs), break down barriers within restrictive payer networks, and accelerate the speed at which patients receive critical therapies.

"Stacy brings exactly the combination of clinical credibility and commercial sophistication this role demands," said Jigar Thakkar, Chief Executive Officer of Longitude Rx, in a statement. "As we expand beyond our founding members, we need a leader who can unify market access, payer strategy, and growth execution into a single commercial engine — and Stacy is that leader."

A Clinical Veteran to Navigate a Complex Market

Walton’s unique career trajectory, from a critical care registered nurse to a C-suite commercial strategist, makes her particularly suited to address the intricate challenges of the specialty pharmacy landscape. Her deep clinical background provides an understanding of the patient journey, while her extensive commercial experience offers the strategic acumen needed to navigate a market dominated by entrenched players.

Before joining Longitude Rx, Walton served as Senior Vice President at Shields Health Solutions, a national firm specializing in hospital-owned specialty pharmacy solutions. There, she was instrumental in driving over $3 billion in revenue through strategic partnerships, supporting more than 80 health systems in optimizing their specialty pharmacy operations. Her work included navigating complex FDA risk evaluation and mitigation strategies (REMS) and championing strategies for new cell and gene therapies.

Her tenure at OptumRx, United Healthcare's pharmacy services arm, further solidified her expertise. As Senior Director of Specialty & Industry Relations, she led national clinical programs for complex conditions like oncology and rare diseases. Notably, she developed a competitive LDD strategy that generated significant revenue and built crucial relationships with biopharma manufacturers, giving her firsthand insight into the contract negotiations and network access challenges that Longitude Rx aims to solve for its partners.

"Having spent my career at the intersection of clinical care and commercial strategy, I know firsthand how much is at stake when a patient can't access the therapy they need," Walton stated. "Longitude Rx is building something genuinely different — infrastructure that health systems own and govern. I'm here to scale that model and make sure more health systems, and more patients, benefit from it."

The Rise of Health System-Owned Pharmacy Solutions

Walton's appointment comes at a pivotal moment for the U.S. healthcare industry. Specialty drugs, which treat complex and chronic conditions, now account for over 50% of total pharmaceutical spending, a figure projected to grow. This has created immense financial pressure on health systems while simultaneously creating access hurdles for the patients they serve.

Historically, large PBMs and their affiliated specialty pharmacies have controlled the dispensing of these high-cost medications. They often create narrow or exclusive networks that lock out hospital-owned pharmacies, even when the patient is receiving all other care within that same health system. This fragmentation leads to care delays, administrative burdens for providers, and a disjointed experience for patients who must navigate an external, often impersonal, pharmacy system.

In response, a growing number of hospitals and health systems are developing their own specialty pharmacies or joining consortiums like Longitude Rx. These Health System-Owned Specialty Pharmacies (HSSPs) leverage a key advantage: integration. By embedding pharmacy services directly within the clinical workflow and providing pharmacists with access to the patient's electronic medical record (EMR), HSSPs can improve medication adherence, streamline communication between care teams, and enhance patient outcomes. This integrated model is a core tenet of Longitude Rx's value proposition.

A Unified Front Against Market Fragmentation

Longitude Rx represents a new phase in this trend, moving from individual HSSPs to a collaborative, system-owned entity with significant market power. The organization was founded by five of the nation's leading non-profit health systems: Baylor Scott & White Health, Memorial Hermann Health System, Michigan Medicine, Novant Health, and Providence. Together, these founding members represent over $60 billion in combined net patient service revenue, giving them collective leverage in negotiations with payers and pharmaceutical manufacturers.

The organization’s strategy is powered by a sophisticated technology backbone. Partnering with Innovaccer, Longitude Rx utilizes a data platform designed to unify fragmented information from EMRs, payers, and pharmacies. This creates a single source of truth for each patient, enabling AI-driven workflows that automate administrative tasks, predict adherence issues, and accelerate the prior authorization and financial assistance processes that often delay care.

By centralizing these capabilities, Longitude Rx aims to provide its health system partners with the infrastructure to capture more in-system prescriptions, optimize performance under the 340B Drug Pricing Program, and ultimately deliver better, more coordinated care. The model is already gaining traction beyond its founders, with Onvida Health recently signing on as the platform's first new health system customer.

With Walton now leading the commercial charge, Longitude Rx is poised to accelerate this expansion. Her focus will be on demonstrating to other health systems that by joining forces, they can reclaim control over a critical part of the care continuum, improve their financial stability, and ensure their patients have timely and reliable access to life-changing specialty medications.